{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:11:56Z","timestamp":1790331116672,"version":"4.1.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombosis is the second leading cause of death in cancer patients and treatment for thrombosis and prevention for secondary prophylaxis is anticoagulation. Low-molecular-weight heparin (LMWH) is more effective than vitamin K antagonists for the treatment of cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) are non-inferior to dalteparin in treating CAT with similar major bleeding risks. Major guidelines recommend DOACs for CAT; however, data comparing individual DOACs to enoxaparin is lacking. The purpose of this study is to evaluate the efficacy and safety of DOACs compared to LMWH for CAT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multi-site retrospective review was conducted in adult cancer patients with a CAT history who received either a DOAC (apixaban or rivaroxaban) or LMWH (enoxaparin). Primary efficacy and safety endpoints were recurrent thromboembolism and major bleeding occurrences. Secondary endpoints included time to subsequent CAT occurrence, time to first bleed event post initial CAT, and incidence of clinically relevant non-major and minor bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 102 patients were included in the study. There was no significant difference among the groups with respect to time to subsequent CAT (p\u2009=\u20090.5625). However, patients who received apixaban and rivaroxaban had a 2.39 times and 3.26 times higher risk of subsequent CAT respectively compared to those who received enoxaparin. Major bleeding rates were also not statistically significant (p\u2009=\u20090.465), despite enoxaparin having the highest rate at 8.8% and no rivaroxaban patients experiencing major bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No differences were observed between rivaroxaban, apixaban, and enoxaparin in rates of recurrent venous thromboembolism (VTE) and bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251331559","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T04:44:52Z","timestamp":1743569092000},"page":"1200-1206","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-7776","authenticated-orcid":false,"given":"Juri","family":"Chung","sequence":"first","affiliation":[{"name":"NYU Langone Hospital\u2013 Long Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Park","sequence":"additional","affiliation":[{"name":"NYU Langone Hospital\u2013 Long Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Chin-Hon","sequence":"additional","affiliation":[{"name":"NYU Langone Hospital\u2013 Long Island"},{"name":"NYU Langone Hospital \u2013 Long Island"},{"name":"NYU Grossman Long Island School of Medicine, Mineola, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Akerman","sequence":"additional","affiliation":[{"name":"NYU Grossman Long Island School of Medicine, Mineola, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hindenburg","sequence":"additional","affiliation":[{"name":"NYU Langone Hospital \u2013 Long Island"},{"name":"NYU Grossman Long Island School of Medicine, Mineola, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460121"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007338"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014"},{"key":"e_1_3_2_9_2","first-page":"95","article-title":"Edoxaban for cancer-associated venous thromboembolism","volume":"379","author":"Raskob GE","year":"2018","unstructured":"Raskob GE, Buller HR, Segers A. Edoxaban for cancer-associated venous thromboembolism. N Engl J Med 2018; 379: 95\u201396.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103"},{"key":"e_1_3_2_13_2","volume-title":"Statistical Methods for Survival Data Analysis","author":"Lee ET","year":"1992","unstructured":"Lee ET. Statistical Methods for Survival Data Analysis. Second ed. New York: John Wiley & Sons, 1992."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-549733"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01428-y"},{"key":"e_1_3_2_16_2","first-page":"179","article-title":"A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban","volume":"6","author":"Frost C","year":"2014","unstructured":"Frost C, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: 179\u2013187.","journal-title":"Clin Pharmacol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251331559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251331559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251331559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:57:02Z","timestamp":1790330222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251331559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251331559"],"URL":"https:\/\/doi.org\/10.1177\/10781552251331559","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}